PTP4A3 and neoplasm: Moreover, research from the Zeng group has shown that PTP4A3 antigens are externalised by tumour cells, making them accessible for the first‐in‐class humanised antibody against PTP4A3, PRL3‐zumab, which is in Phase 2 trials (NCT04452955) [12, 13].